Print Friendly, PDF & Email

NCT/Study#

NA /

P153CV-RAS-001

Phase I Study Dose Finding Study To Evaluate Safety, Reactogenicity And Immunogenicity Of CV09040102 RAS G12D Mrna Vaccine In HLA- Selected Patients With Pancreatic Cancer Or Colorectal Cancer Harboring The RAS G12D Mutation

DISEASE GROUP:
Phase 1 Clinical Trials
current phase:
Phase I
STUDY STATUS:
Active
Location:
Hackensack, NJ
For More information: